908244-98-4

Basic information

• Product Name: 4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER;Methyl 4-Methylnipecotate;Methyl 4-Methylpiperidine-3-carboxylate hcl;Methyl 4-methylpiperidine-3-carboxylate
• CAS NO: 908244-98-4
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.21
• Product Categories: Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 908244-98-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER(908244-98-4)
• EPA Substance Registry System: 4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER(908244-98-4)

Safety Data

• Hazardous Substances Data: 908244-98-4(Hazardous Substances Data)

Usage

Description

4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER, also known as Methyl 4-Methylnipecotate, is an organic compound that serves as an intermediate in the synthesis of various piperidine derivatives. These derivatives have potential applications as inhibitors and therapeutic agents due to their unique chemical properties and structural features.

Uses

Used in Pharmaceutical Industry:
4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER is used as a chemical intermediate for the synthesis of piperidine derivatives in the pharmaceutical industry. These derivatives are valuable for their potential as inhibitors and therapeutic agents, contributing to the development of new medications and treatments for various diseases and conditions.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER is utilized as a key component in the creation of various piperidine-based compounds. Its role in these syntheses allows for the exploration of new chemical pathways and the discovery of novel compounds with potential applications in various industries.

Upstream product

• 3430-22-6 3-Bromo-4-methylpyridin 
• 3222-50-2 4-methylnicotinic acid 
• 33402-75-4 4-methylnicotinic acid methyl ester 

Downstream Products

• 1201192-62-2 1-(tert-butyl) 3-methyl 4-methylpiperidine-1,3-dicarboxylate 
• 1009376-52-6 1-(tert-butoxycarbonyl)-4-methylpiperidine-3-carboxylic acid 
• 1207853-61-9 trans-racemic tert-butyl 3-amino-4-methylpiperidine-1-carboxylate 
• 1271810-25-3 trans 1-(tert-butoxycarbonyl)-4-methylpiperidine-3-carboxylic acid 

Relevant articles and documents

9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

[1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND

The present invention relates to a novel [l,2,4]triazolo[l,5-a]pyrimidin-yl derivative of formula (1) as inhibitor of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compound, to processes for preparing such compound and compositions, and to the use of such compound and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.